Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →CBB-120 demonstrated synergistic potency both in vitro and in vivo, leading to tumor regression in multiple xenografts representing breast, lung, colon,…
Biotech entrepreneur Michael Torres is selling his antibody-drug conjugate startup CrossBridge Bio to Eli Lilly in a deal worth up to $300 million.…
On Tuesday, Eli Lilly and Co. (NYSE:LLY) announced that it would acquire Houston-based CrossBridge Bio Inc., which was founded in 2023 to develop…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Eli Lilly agreed to acquire Houston-based ADC specialist CrossBridge Bio for up to $300M (undisclosed upfront + development milestone). Lead asset CBB-120 is a preclinical TROP2-targeting dual-payload (TOP1i + ATRi) ADC positioned to differentiate from existing TROP2 ADCs. Extends Lilly's precision oncology build-out post Loxo.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / CrossBridge Bio, Inc. (this deal) | 2026 | $300M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Oncology deals